Sanofi (NASDAQ:SNY – Get Free Report) released its earnings results on Friday. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.56 by $0.48, Zacks reports. Sanofi had a return on equity of 15.24% and a net margin of 8.70%. The firm had revenue of $17.25 billion for the quarter, compared to analyst estimates of $14.30 billion. During the same quarter last year, the firm posted $2.91 EPS. The company’s revenue was up 16.2% on a year-over-year basis.
Here are the key takeaways from Sanofi’s conference call:
- Q3 performance was strong: sales rose 14.3% to €14.4 billion, business operating income increased 19.7%, and business EPS grew 19.6%, supported by demand, favorable gross-to-net adjustments, product mix, and strict cost control.
- Sanofi upgraded its 2026 outlook to sales growth of 13%–15% and business EPS growth of 15%–17%. Management also expects business operating income and margin to increase annually through 2030, despite upcoming headwinds.
- Dupixent remained the central growth engine, generating €5.7 billion in Q3 with more than 1.5 million patients globally. Sanofi reaffirmed confidence in reaching at least €25 billion in annual sales by 2030 and expanded its Regeneron alliance with four next-generation immunology antibodies, including a potential long-acting follow-on product.
- Sanofi is concentrating resources on immunology, rare diseases, and vaccines while pursuing late-stage and commercial assets through disciplined BD and M&A. The company expects to provide more detail on its disease-area priorities, capital allocation, and Dupixent loss-of-exclusivity planning at a strategic update before year-end.
- R&D productivity remains a concern, with management acknowledging that Sanofi’s pipeline lags peers and discontinuing amlitelimab and itepekimab after benefit-risk reviews. The company also cautioned that 2027 sales will face roughly €1.3 billion of divestment-related reductions, a return to slightly negative pricing trends, and continued Dupixent profit-sharing and reimbursement headwinds.
Sanofi Price Performance
Shares of NASDAQ:SNY opened at $44.34 on Monday. Sanofi has a 12 month low of $39.07 and a 12 month high of $52.68. The company’s 50-day moving average price is $42.21 and its two-hundred day moving average price is $44.35. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. The firm has a market cap of $107.50 billion, a P/E ratio of 21.95, a P/E/G ratio of 1.37 and a beta of 0.31.
Analyst Ratings Changes
Several research firms recently weighed in on SNY. HSBC reiterated a “buy” rating on shares of Sanofi in a research note on Thursday, September 10th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research note on Thursday, October 1st. Royal Bank Of Canada began coverage on Sanofi in a report on Tuesday, September 8th. They issued a “sector perform” rating for the company. Berenberg Bank reiterated a “buy” rating on shares of Sanofi in a research report on Monday, October 5th. Finally, UBS Group reissued a “neutral” rating on shares of Sanofi in a report on Thursday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Sanofi presently has a consensus rating of “Hold” and an average target price of $49.50.
Read Our Latest Analysis on SNY
About Sanofi
Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.
The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.
Featured Stories
- Five stocks we like better than Sanofi
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
